

# **Evaluation of the Prognostic Value of the Prechemotherapy Platelet to Lymphocyte Ratio in Malignant Pleural Mesothelioma**

*Thesis*

*Submitted for Partial Fulfillment of Master Degree  
in Clinical Oncology and Nuclear Medicine*

*By*

**Mira Youssef Canaan**

*M.B.B.Ch*

*Under Supervision of*

**Prof. Dr. Eman Mohamed Tawfik El Sheikh**

*Professor of Clinical Oncology and Nuclear Medicine  
Faculty of Medicine, Ain Shams University*

**Prof. Dr. Nada Ezz El Din Gomaa**

*Researcher Professor of Pulmonology  
National Research Center*

**Dr. Ramy Refaat Youssef Ghali**

*Ass. Professor of Clinical Oncology and Nuclear Medicine  
Faculty of Medicine, Ain Shams University*

**Dr. Wesam El Ghamry**

*Lecturer of Clinical Oncology and Nuclear Medicine  
Faculty of Medicine, Ain Shams University*

*Faculty of Medicine  
Ain Shams University*

**2018**



## Acknowledgement

First and foremost, thanks to **God** the most merciful and the most compassionate to whom I relate any success in achieving any work in my life.

I would like to thank my mother, father, brother, husband and daughter for bearing a lot with me so I can achieve this work.

Words cannot express my deep gratitude and sincere appreciation to **Prof. Dr. Eman El Sheikh**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine - Ain Shams University for helping me to achieve this thesis.

I would like to thank **Prof. Dr. Nada Ezz Eldin**, Researcher Professor of Pulmonology at National Research Center. Her invaluable comments and remarks were of utmost importance to me.

I would like to express my gratitude to **Prof. Ass. Dr. Ramy Ghali**, Assistant Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine- Ain Shams University. I would like to express my great thanks for the attention to each detail and for learning me a lot in the Oncology field.

I would like to express my very great appreciation to **Dr. Wesam Elghamry**, Lecturer of Clinical Oncology and Nuclear Medicine, Faculty of Medicine - Ain Shams University, for their help and valuable advice throughout the performance of this work.

A special thanks to **Dr. Gehane Hamdy**, Researcher of Pulmonology, National Research Center, Internal Medicine Department for her great contribution and her valuable advices

*✍ Mira Canaan*

# Contents

List of Abbreviations .....	I
List of Tables .....	VI
List of Figures .....	VIII
<b>Introduction .....</b>	<b>1</b>
<b>Aim of the Work .....</b>	<b>6</b>
<b>Review of Literature .....</b>	
• Chapter (1): Epidemiology and Risk Factors .....	7
• Chapter (2): Diagnosis .....	19
• Chapter (3): Treatment .....	47
• Chapter (4): Prognostic Factors .....	72
• Chapter (5): Platelet to Lymphocytes Ratio in Malignant Pleural Mesothelioma .....	86
<b>Patients and Methods .....</b>	<b>96</b>
<b>Results .....</b>	<b>100</b>
<b>Discussion .....</b>	<b>132</b>
<b>Conclusion .....</b>	<b>153</b>
<b>Recommendations .....</b>	<b>155</b>
<b>Summary .....</b>	<b>157</b>
<b>References .....</b>	<b>160</b>
<b>Arabic Summary .....</b>	<b>--</b>

## List of Abbreviations

<b>Abb.</b>	<b>Description</b>
<b>ACR</b>	American College of Radiology
<b>AJCC</b>	American Joint Committee on Cancer
<b>ASIR W</b>	Age-standardized incidence rates (world population)
<b>ASTRO</b>	American Society of Radiation Oncology
<b>BAP1</b>	BRCA1 associated protein 1
<b>CALGB</b>	Cancer and Leukemia Group B
<b>CBC</b>	Complete blood count
<b>CD44</b>	Molecule
<b>CI</b>	Confidence interval
<b>CK5/6</b>	Cytokeratin 5/6
<b>CR</b>	Complete response
<b>CRP</b>	C-reactive protein
<b>CRT</b>	Concurrent chemoradiotherapy
<b>CT</b>	Chemotherapy
<b>CT</b>	Computed tomography
<b>CTLA</b>	Cytotoxic T lymphocyte associated antigen
<b>CTV</b>	Clinical target volumes
<b>DAMP</b>	Damage associated molecular pattern
<b>DCR</b>	Disease control rate
<b>Df</b>	Degree of freedom
<b>DFS</b>	Disease free survival
<b>ECOG</b>	Eastern Cooperative Oncology Group
<b>EGFR</b>	Epidermal growth factor receptor

<b>Abb.</b>	<b>Description</b>
<b>EMA</b>	Epithelial membrane antigen
<b>EORTC</b>	European Organization for Research and Treatment of Cancer
<b>EPP</b>	Extrapleural pneumonectomy
<b>ERCC1</b>	Excision cross-complementation group 1
<b>FDA</b>	Food and Drug Administration
<b>FDG</b>	Fluorodeoxyglucose
<b>FISH</b>	Fluorescent in situ hybridization
<b>GBD</b>	Global Burden of Disease
<b>GLUT-1</b>	Glucose transporter 1
<b>GPS</b>	Glasgow Prognostic Score
<b>Gy</b>	Grey
<b>HCRT</b>	Highly conformal RT
<b>HCV</b>	Hepatitis C virus
<b>HIOC</b>	Heated intraoperative chemotherapy lavage
<b>HMGB1</b>	High mobility group box 1 protein
<b>HR</b>	Hazard ratio
<b>IARC</b>	International Agency for Research on Cancer
<b>IASLC</b>	International Association for the Study of Lung Cancer
<b>ICC</b>	Immunocytochemistry
<b>IgG</b>	Immunoglobulin G
<b>IHC</b>	Immunohistochemistry
<b>IL</b>	Interleukin
<b>IMIG</b>	International Mesothelioma Interest group
<b>IMP3</b>	Insulin like-growth factor II messenger RNA-binding protein 3

<b>Abb.</b>	<b>Description</b>
<b>IMRT</b>	Intensity modulated radiotherapy
<b>mAbs</b>	Monoclonal antibodies
<b>MAPS</b>	Mesothelioma Avastin Cisplatin Pemetrexed Study
<b>MARS</b>	Mesothelioma and Radical Surgery
<b>MCAM</b>	Melanoma cell adhesion molecule
<b>MCR</b>	Macroscopic complete resection
<b>MDM2</b>	Murine double minute 2
<b>MH</b>	Mesothelial hyperplasia
<b>miRNA</b>	Micro ribonucleic acid
<b>MLD</b>	Mean lung dose
<b>MM</b>	Malignant mesothelioma
<b>MPF</b>	Megakaryocyte potentiating factor
<b>MPM</b>	Malignant pleural mesothelioma
<b>MR</b>	Mortality rate
<b>mRECIST</b>	Modified response evaluation crieteria in solid tumors
<b>MRI</b>	Magnetic resonance imaging
<b>mRNA</b>	Messenger ribonucleic acid
<b>MW</b>	Mineral wool
<b>NCCN</b>	National Comprehensive Cancer Network
<b>NCI</b>	National Cancer Institute
<b>NF2</b>	Neurofibromin 2
<b>NK</b>	Cells natural killer cells
<b>NLR</b>	Neutrophil to lymphocyte ratio
<b>NSCLC</b>	Non small cell lung cancer

<b>Abb.</b>	<b>Description</b>
<b>OP</b>	Osteopontin
<b>OR</b>	Overall response
<b>ORR</b>	Overall response rate
<b>OS</b>	Overall survival
<b>P53</b>	Tumor protein p53
<b>PD</b>	Partial response
<b>PD</b>	Pleurectomy decortication
<b>PD</b>	Programmed death receptor
<b>PDL1</b>	Programmed death ligand-1
<b>PET</b>	Positron emission tomography
<b>PFS</b>	Progression-free survival
<b>PI</b>	Prognostic index
<b>PLR</b>	Platelet to lymphocyte ratio
<b>PR</b>	Partial response
<b>pRb</b>	Retinoblastoma protein
<b>PTV</b>	Planning target volume
<b>QoL</b>	Quality of life
<b>R0</b>	Complete resection
<b>R1</b>	Microscopic resection
<b>R2</b>	Macroscopic resection
<b>RANTES</b>	Regulated on Activation, Normal T-cell-Expressed and Secreted
<b>RT</b>	Radiotherapy
<b>SD</b>	Standard deviation
<b>SE</b>	Standard error
<b>SEER</b>	Surveillance, Epidemiology, and End Results

<b>Abb.</b>	<b>Description</b>
<b>SIR</b>	Systemic inflammatory response
<b>SMRP</b>	Soluble mesothelin-related protein
<b>SUV</b>	Standard uptake volume
<b>SV40</b>	Simian virus
<b>SWOG</b>	South West Oncology Group
<b>TIL</b>	Tumor-infiltrating lymphocytes
<b>TMT</b>	Trimodality therapy
<b>TNM</b>	Tumor-node-metastasis
<b>TTF-1</b>	Thyroid transcription factor-1
<b>UICC</b>	Union for International Cancer Control
<b>UK</b>	United Kingdom
<b>US</b>	Ultra sound
<b>US</b>	United States
<b>VATS</b>	Video assisted thoracoscopic surgery
<b>VEGF</b>	Vascular endothelial growth factor
<b>VEGFR</b>	Vascular endothelial growth factor receptor
<b>WBC</b>	White blood cells
<b>WHO</b>	World health organization



## List of Tables

Table	Title	Page
1	AJCC 7 <sup>th</sup> edition, staging of malignant pleural mesothelioma	45
2	AJCC 8 <sup>th</sup> edition of TNM classification if Malignant pleural mesothelioma from International Mesothelioma Interest Group	46
3	TNM Stage Groupings Proposed for the Eighth Edition of MPM Staging System Relative to Those Used in the Seventh Edition	46
4	Demographic of study population	101
5	Clinical presentation data in patients with MPM	102
6	TNM classification of MPM according to AJCC 7th edition	104
7	Mean and median PFS of the whole studied population	105
8	Mean and median OS of the whole study population	107
9	Comparison between both groups in 1st line chemotherapy as regard OS	110
10	The relation between both groups of first line chemotherapy and PFS	112

<b>Table</b>	<b>Title</b>	<b>Page</b>
<b>11</b>	Correlation between gender and PLR	114
<b>12</b>	Correlation between ECOG and PLR	115
<b>13</b>	correlation between PLR and tumor stage according to AJCC	116
<b>14</b>	Different patterns of response among different PLR groups	117
<b>15</b>	Correlation between PLR and PFS	118
<b>16</b>	Correlation between median PFS and the two groups of PLR	119
<b>17</b>	Test of significance between PFS and PLR subgroups	119
<b>18</b>	Correlation between PLR and OS	121
<b>19</b>	Correlation between median estimated OS and the two groups of PLR	122
<b>20</b>	Test of significance between OS and PFS subgroups	122
<b>21</b>	The relation between OS within platinum-gemcitabine group	126
<b>22</b>	Progression free survival within the platinum-pemetrexed group	128
<b>23</b>	The relation between PFS within platinum-gemcitabine group	130

## List of Figures

<b>Figure</b>	<b>Title</b>	<b>Page</b>
<b>1</b>	Mesothelioma in some countries. Age standerized (world) incidence rates	11
<b>2</b>	Map of greater Cairo Industrial areas highly polluted with asbestos	13
<b>3</b>	Unilateral Right nodular circumfrential malignant pleural mesothelioma, usually post tapping. Pulmonary window (left) and mediastinal window	22
<b>4</b>	Cytomorphology of the epithelioid mesothelioma cells in effusion	32
<b>5</b>	Histological samples of malignant pleural mesothelioma	35
<b>6</b>	CT scan before and after induction chemotherapy showing a partial remission according to RECIST criteria	69
<b>7</b>	Example of measurement of a single computed tomography scan slice	71
<b>8</b>	Presenting the histological subtypes in MPM	103
<b>9</b>	Progression free survival of the whole study population	106
<b>10</b>	Presenting the OS of the whole study population	107
<b>11</b>	Response to 1st line chemotherapy in percentages	109
<b>12</b>	Illustrating overall survival in both groups of first	111

<b>Figure</b>	<b>Title</b>	<b>Page</b>
	line chemotherapy	
<b>13</b>	Graph illustrating progression free survival in both groups of first line chemotherapy	113
<b>14</b>	Correlation between gender and PLR	114
<b>15</b>	Correlation between ECOG and PLR	115
<b>16</b>	Kaplan-meier curve illustrating the relationships between PFS and different PLR groups	120
<b>17</b>	Kaplan-meier curve illustrating OS for the study population	123
<b>18</b>	Graph illustrating OS within the platinum-pemetrexed	125
<b>19</b>	Graph illustrating OS within the platinum-gemcitabine	127
<b>20</b>	Graph illustrating PFS within the platinum-pemetrexed	129
<b>21</b>	Graph illustrating PFS within the platinum-gemcitabine	131



---

# Introduction

---





---

# Aim of the Work

---





---

## Chapter (1)

# **Epidemiology and Risk Factors**

---

